New York, United States – November 10, 2025 – Internationally acclaimed interventional oncologist and medical innovator Dr. Jeff Geschwind is scheduled to speak at the world-renowned Veith Symposium 2025, one of the foremost global conferences in vascular and endovascular medicine. His session, to be held on Thursday, November 20, will take place under the AIM at Veith program, where Dr. Geschwind will share his latest insights on the latest trends in the management of patients with hepatocellular carcinoma including the continued role of transarterial chemoembolization.
For more than four decades, the Veith Symposium has provided leading physicians, surgeons, and researchers from around the world a forum to exchange knowledge, discuss emerging technologies, and debate pressing clinical challenges in vascular medicine. This year’s event will be held from November 18–22, 2025, at the New York Hilton Midtown, and is expected to feature over 1,300 fast-paced presentations covering cutting-edge topics in vascular, endovascular, and oncologic care.
Dr. Geschwind’s participation highlights his continued dedication to advancing interventional oncology—a field he helped pioneer and shape into one of the most dynamic areas in modern medicine. His presentations will emphasize the need for multidisciplinary collaboration that bridges imaging, research, and clinical data to improve patient outcomes. “The Veith Symposium has long been considered the meeting of reference for vascular medicine,” said Jeff Geschwind, MD. “I am especially happy that the AIM symposium was given a dedicated day this year during the Veith Symposium to present the latest data to interventional radiologists and other specialties. It is therefore an honor to share the stage with global experts and contribute to the continued growth of interventional oncology”.
About the Veith Symposium
The Veith Symposium addresses a critical need in global healthcare: bridging the gap between medical practice and the latest advances in vascular and endovascular treatment. The conference provides an accredited platform for physicians to earn CME credits while engaging in discussions on new techniques, technologies, and therapeutic strategies. Topics range from pharmacologic and surgical innovations to imaging breakthroughs, ensuring that participants receive the most current, unbiased, and evidence-based education available.
Jointly accredited by the Cleveland Clinic Center for Continuing Education, the symposium awards up to 45.75 AMA PRA Category 1 Credits™, affirming its importance as one of the most credible continuing education opportunities for vascular and interventional specialists. Each year, the Veith Symposiumt fosters dialogue between experts, challenges established conventions, and promotes clinical excellence through over a thousand presentations, panel discussions, and video case studies.
About Dr. Jeff Geschwind
Dr. Jeff Geschwind currently serves as the Medical Director for Oncology, Image-Guided Therapy, and Imaging Core Lab at NAMSA, one of the largest clinical research organizations in the United States. He is also a Medical Advisor to HistoSonics, a company developing non-invasive image-guided therapy for cancer, and a consultant for Cage Pharma—a firm he founded in 2009 that develops cancer drugs targeting tumor metabolism. Additionally, Dr. Geschwind acts as a scientific consultant for Philips Healthcare, advising on oncology and image-guided technologies.
Dr. Geschwind’s distinguished academic background began at the University of Pennsylvania and Boston University School of Medicine, followed by residency training at the University of California, San Francisco as an NIH Resident-Scholar.
He later completed his fellowship training in Vascular and Interventional Radiology at Johns Hopkins University School of Medicine, and remained on faculty after completing his training, eventually becoming Professor of Radiology, Surgery, and Oncology and Director of the Division of Vascular and Interventional Radiology.
Over his career, Dr. Geschwind has published nearly 300 peer-reviewed scientific manuscripts, authored the first textbook on Interventional Oncology, and co-edited Abram’s Angiography, a leading reference in interventional radiology. His research in tumor metabolism and targeted liver cancer therapies has earned multiple NIH grants, philanthropic funding, and industry recognition. Notably, his Google Scholar H-index of 86 places him among the most cited radiologists in the world—reflecting the lasting impact of his scientific work.
After nearly two decades at Johns Hopkins, Dr. Geschwind was recruited to Yale School of Medicine as Chairman of Radiology and Biomedical Imaging and Radiologist-in-Chief at Yale-New Haven Hospital. There, he established a new laboratory dedicated to liver cancer and interventional oncology, supported by major NIH funding. His leadership has helped advance minimally invasive cancer treatment, inspiring a new generation of physicians and researchers committed to medical innovation.
Advancing the Future of Image-Guided Oncology
Dr. Geschwind’s session at the AIM at Veith program will underscore the importance of integrating cancer biology, imaging science, and clinical outcomes into a unified framework for patient-centered care. His contributions not only redefine how patients with liver cancer are treated but also reinforce the vital role of interventional radiology in the broader medical landscape.
The Veith Symposium 2025 promises to be a milestone event for the medical community, offering new insights, interactive learning opportunities, and international collaboration.
For more information on the event, visit www.veithsymposium.org.
To learn more about Dr. Jeff Geschwind’s research, publications, and professional achievements, visit https://jeffgeschwind.com.
Media Contact:
Press Office – Dr. Jeff Geschwind
Website: https://jeffgeschwind.com
Media Contact
Company Name: Veith Symposium
Contact Person: Jeff Geschwind
Email: Send Email
Country: United States
Website: https://jeffgeschwind.com/